Archive
555 articles, sorted by publication time.
The Doherty Institute said a recombinant flu vaccine induced a stronger immune response in a clinical trial; this offers clues for updating seasonal flu vaccine technology, but currently available public information is still insufficient to determine whether it can truly reduce infection and severe disease.
The new collaboration between Insilico Medicine and SK Biopharmaceuticals again raises the commercial ceiling for AI drug development; but in neuroimmunology, what is truly scarce is not the speed of producing candidate molecules, but evidence that can pass through human biology and clinical validation.
SOT201 is attempting to address a longstanding challenge in cancer immunotherapy: waking up anti-tumor T cells without also igniting inflammation throughout the body. Early human testing has only just begun, and the signals remain very preliminary, but it sketches the design direction for next-generation cytokine therapies.
Insilico Medicine and SK Biopharmaceuticals have signed a major collaboration, once again raising commercial expectations for AI-designed molecules; but in neuroimmune and central nervous system diseases, the speed of algorithms is only the starting point, while clinical biology remains the strictest hurdle.
The oversubscribed financing pushes a new company directly onto the clinical stage and also reminds the market that, as inflammatory disease treatment moves toward greater precision, funding enthusiasm must still be tested by human evidence.
In an era when immuno-inflammatory therapies are becoming increasingly precise and increasingly expensive, a large Series A financing puts Bionyra Pharma directly on the early-stage biotech stage; but publicly available information remains limited, and the real test is still whether its candidate antibodies can pass through the narrow gate of clinical evidence.
A progress report at an industry conference is often a point where capital, the market, and the regulatory path intersect for an early-stage biotech company; but behind an announcement with limited information, what can truly change valuation and medical expectations remains verifiable clinical data.
Between the pressure of antimicrobial resistance and the burden of inpatient treatment, an oral drug for certain adult patients has obtained U.S. approval; it is not a signal for broad use, but rather a narrow additional option for infection settings where choices are scarce.
The new office means organoids, human tissue models, and AI simulations are no longer just marginal experiments among alternatives; the real challenge is turning them into a shared language that research funding, drug review, and safety assessment are all willing to accept.
Research by a Harvard and Beth Israel team shows that OpenAI o1 outperformed physician controls on multiple text-based clinical reasoning tasks; this is an important signal for medical AI, but still not a pass to hand diagnosis over to machines.
This international program applies generative structural models to SLC transporter drug discovery, with the goal not of immediately producing answers for new drugs, but of shortening the trial-and-error distance in early molecular screening and design.
An early-stage clinical trial has added controlled-release niacin to standard treatment, with preliminary progression-free survival higher than historical controls; but before it can become a therapy, it still faces hurdles including small size, non-randomization, and safety monitoring.